Akston Biosciences, a United States-based company that deals with insulin engineering, has collaborated with LakePharma, a United States-based CRDMO serving the biotechnology community, to produce commercial quantities of Akston's adjuvated COVID-19 vaccine candidate, AKS-452, it was reported on Tuesday.
The vaccine candidate is scheduled to commence phase 1/2 clinical testing later this month.
AKS-452 is a COVID-19-specific Fc fusion protein vaccine that is in commercial development and is designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain of the novel SARS-CoV-2 coronavirus spike protein. It is shelf-stable for weeks at up to 37 degrees Celsius and is engineered to use conventional antibody manufacturing techniques.
CDT signs SAFE note with Pep'd to expand US peptide market exposure
Astellas doses first patient in Phase 3 study of ASP2138
Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia
United Therapeutics wins FDA acceptance for ralinepag PAH filing
Takeda wins Japan approval for ORZEYFUL to treat underlying cause of narcolepsy type 1
Acadia wins EU approval for DAYBU as first treatment for Rett syndrome
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer